Detailed data from a Phase 2b/3 study of Merck’s treatment clesrovimab should support the company’s efforts to win approval ...

Merck's (MRK) monoclonal antibody clesrovimab shows cuts RSV infections by 60% in infants, with a strong safety profile. Read ...

Merck reported positive results for its experimental treatment designed to protect infants from RSV. The mid to late-stage ...

Merck’s investigational antibody clesrovimab demonstrated more than 60% effectiveness in reducing some types of respiratory ...

Highlights:,Merck & Co Inc's experimental treatment, clesrovimab, has demonstrated positive results in a mid- to late-stage ...

A Phase IIb/III trial with infants entering their first respiratory syncytial virus (RSV) season met its primary endpoints.

Merck presents positive results from phase 2b/3 trial of clesrovimab, an investigational RSV preventative monoclonal antibody at IDWeek 2024: Rahway, New Jersey Saturday, October ...

Wall Street promptly began trying to weigh the compound’s marketplace odds after Merck & Co. Inc. detailed positive data from the phase IIb/III trial known as MK-1654-004 with clesrovimab, an ...

Merck announces positive results from Phase 2b/3 and interim Phase 3 trials of a monoclonal antibody designed to protect infants from RSV.

New data released by Merck suggests AstraZeneca and Sanofi’s Beyfortus, the monoclonal antibody injection that protects ...

In the study, clesrovimab (MK-1654) significantly reduced the incidence of RSV disease and hospitalisations in healthy ...

Current health news covers Gilead's withdrawal of a cancer drug, Texas' lawsuit against a doctor for providing ...